SNY
Sanofi
$44.25
+0.32%
$107.9B
No data for this timeframe.
Vol
Market Cap$107.9B
Cap SizeLarge Cap
Inst. Holders50 funds
Inst. Value$6.4B
Inst. Activity21 buys / 20 sells
SEC Reports1
Recent Activity
May 10, 2026
SEC
A federal district court partially denied Sanofi's motion to dismiss an employment discrimination lawsuit, allowing race
COURT-RULING — Impact 3/10
Inst.
DODGE & COX — TRIM
29,504,632 shares ($1.4B)
Inst.
MORGAN STANLEY — ADD
12,511,867 shares ($602.8M)
Jun 9, 2026
clinical_trial_readout
Results Pending: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 (Phase 2) — Completed 18d ago
Trial: A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Partic
May 28, 2026
Event
Lovenox
WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are antico
Apr 13, 2026
Event
Osinubi v. Sanofi Pasteur Biologics, LLC
Court ruling from District Court, D. Massachusetts. Docket: 1:25-cv-12262
Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$55.90 (Jan 2026)
Current $44.25
Low $51.00
Median $54.50
High $63.00
9 analysts
$51.00
$63.00
Analyst Ratings
7Strong Buy
9Buy
12Hold
1Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jan 16, 2026 | UBS | DOWNGRADE | Buy → Neutral |
| Jan 6, 2026 | Barclays | DOWNGRADE | Overweight → Equal-Weight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $1.13 ▲ +1.4% | $1.13 — $1.13 | 24% YoY | 1 |
| Next Q | $1.65 ▲ +12.9% | $1.65 — $1.65 | -3% YoY | 1 |
| Current FY | $4.98 ▲ +3.5% | $4.81 — $5.10 | 7% YoY | 5 |
| Next FY | $5.29 ▲ +1.9% | $4.85 — $5.45 | 6% YoY | 5 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| DODGE & COX | $1.4B | TRIM |
| MORGAN STANLEY | $602.8M | ADD |
| BANK OF AMERICA CORP | $457.0M | — |
| FRANKLIN RESOURCES INC | $345.2M | ADD |
50 institutional holders with $6.4B total value (132,901,889 shares) as of 2026-Q1. Top holders: NOMURA, DODGE, MORGAN. Net buying activity: 21 institutions added/increased vs 20 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | DODGE & COX | 29,504,632 | $1.4B | 22.2% | TRIM -47.8% |
| 3 | MORGAN STANLEY | 12,511,867 | $602.8M | 9.4% | ADD +37.5% |
| 4 | BANK OF AMERICA CORP /DE/ | 9,484,350 | $457.0M | 7.1% | — |
| 5 | FRANKLIN RESOURCES INC | 7,165,193 | $345.2M | 5.4% | ADD +40.5% |
| 6 | Invesco Ltd. | 6,621,539 | $319.0M | 5.0% | — |
| 7 | BARROW HANLEY MEWHINNEY & STRAUSS LLC | 5,887,466 | $283.7M | 4.4% | — |
| 8 | FEDERATED HERMES, INC. | 4,754,359 | $229.1M | 3.6% | ADD +30.5% |
| 9 | FMR LLC | 4,010,161 | $193.2M | 3.0% | — |
| 10 | ENVESTNET ASSET MANAGEMENT INC | 3,861,894 | $186.1M | 2.9% | — |
| 11 | RAYMOND JAMES FINANCIAL INC | 3,812,745 | $183.7M | 2.9% | — |
| 12 | BRANDES INVESTMENT PARTNERS, LP | 3,723,100 | $179.4M | 2.8% | ADD +27.8% |
| 13 | WELLS FARGO & COMPANY/MN | 3,415,115 | $164.5M | 2.6% | — |
| 14 | BlackRock, Inc. | 3,183,600 | $153.4M | 2.4% | TRIM -40.4% |
| 15 | ROYAL BANK OF CANADA | 3,155,080 | $152.0M | 2.4% | — |
| 16 | GOLDMAN SACHS GROUP INC | 2,582,456 | $124.4M | 1.9% | — |
| 17 | BARCLAYS PLC | 2,356,559 | $113.5M | 1.8% | — |
| 18 | Alyeska Investment Group, L.P. | 2,306,229 | $111.1M | 1.7% | NEW |
| 19 | Connor, Clark & Lunn Investment Management Ltd. | 2,223,301 | $107.1M | 1.7% | DOUBLED +117.2% |
| 20 | Nuveen, LLC | 1,911,226 | $92.1M | 1.4% | TRIM -50.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| DODGE & COX | TRIM | 56,492,599 | 29,504,632 | -47.8% | $1.4B | 2026-Q1 |
| MORGAN STANLEY | ADD | 9,102,196 | 12,511,867 | +37.5% | $602.8M | 2026-Q1 |
| FRANKLIN RESOURCES INC | ADD | 5,100,097 | 7,165,193 | +40.5% | $345.2M | 2026-Q1 |
| FEDERATED HERMES, INC. | ADD | 3,642,307 | 4,754,359 | +30.5% | $229.1M | 2026-Q1 |
| BRANDES INVESTMENT PARTNERS, LP | ADD | 2,913,256 | 3,723,100 | +27.8% | $179.4M | 2026-Q1 |
| BlackRock, Inc. | TRIM | 5,345,618 | 3,183,600 | -40.4% | $153.4M | 2026-Q1 |
| Alyeska Investment Group, L.P. | NEW | — | 2,306,229 | — | $111.1M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | DOUBLED | 1,023,626 | 2,223,301 | +117.2% | $107.1M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | NEW | — | 833,780 | — | $40.2M | 2026-Q1 |
| Cullen Capital Management, LLC | ADD | 360,777 | 593,301 | +64.5% | $28.6M | 2026-Q1 |
| M&T BANK CORP | DOUBLED | 10,531 | 426,657 | +3951.4% | $20.6M | 2026-Q1 |
| Vident Advisory, LLC | ADD | 239,578 | 351,952 | +46.9% | $17.0M | 2026-Q1 |
| TD Waterhouse Canada Inc. | DOUBLED | 5,970 | 240,771 | +3933.0% | $11.5M | 2026-Q1 |
| Beacon Pointe Advisors, LLC | DOUBLED | 21,154 | 194,941 | +821.5% | $9.4M | 2026-Q1 |
| Grantham, Mayo, Van Otterloo & Co. LLC | ADD | 98,171 | 189,071 | +92.6% | $9.1M | 2026-Q1 |
| GQG Partners LLC | ADD | 120,946 | 164,705 | +36.2% | $7.9M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 163,625 | 121,790 | -25.6% | $5.9M | 2026-Q1 |
| HSBC HOLDINGS PLC | TRIM | 205,917 | 107,689 | -47.7% | $5.2M | 2026-Q1 |
| CAPTRUST FINANCIAL ADVISORS | ADD | 65,431 | 106,385 | +62.6% | $5.1M | 2026-Q1 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | ADD | 82,623 | 106,888 | +29.4% | $5.1M | 2026-Q1 |
| CIBC Asset Management Inc | ADD | 71,467 | 90,311 | +26.4% | $4.4M | 2026-Q1 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | TRIM | 113,852 | 84,435 | -25.8% | $4.1M | 2026-Q1 |
| Orion Porfolio Solutions, LLC | TRIM | 93,600 | 61,915 | -33.9% | $3.0M | 2026-Q1 |
| Envestnet Portfolio Solutions, Inc. | TRIM | 79,572 | 53,075 | -33.3% | $2.6M | 2026-Q1 |
| BLAIR WILLIAM & CO/IL | DOUBLED | 4,381 | 43,593 | +895.0% | $2.1M | 2026-Q1 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 3.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Jan 2026): 55% buy across 29 analysts — 7 strong buy, 9 buy, 12 hold, 1 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$55.90 mean target (Jan 2026)
$51.00 Low
$63.00 High
| Metric | Value |
|---|---|
| Current Price | $44.25 |
| Target Low | $51.00 |
| Target Mean | $55.90 |
| Target Median | $54.50 |
| Target High | $63.00 |
| # Analysts | 9 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$1.13 | $1.13 | $1.13 | 24.3% | +1.4% | — | $11.0B | 10.0% | 1 |
| Next Q 2026-09-30 |
$1.65 | $1.65 | $1.65 | -2.7% | +12.9% | — | $13.5B | 8.2% | 1 |
| Current FY 2026-12-31 |
$4.98 | $4.81 | $5.10 | 6.6% | +3.5% | 2↑ 0↓ | $47.1B | 7.9% | 5 |
| Next FY 2027-12-31 |
$5.29 | $4.85 | $5.45 | 6.2% | +1.9% | 2↑ 0↓ | $50.0B | 6.2% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $1.130 | |
| 7d ago | $1.110 | +0.020 |
| 30d ago | $1.115 | +0.016 |
| 60d ago | $1.115 | +0.016 |
| 90d ago | $1.067 | +0.063 |
2 analyst firms have rated this stock: 0 upgrades, 2 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jan 16, 2026 | UBS | DOWNGRADE | Buy | Neutral |
| Jan 6, 2026 | Barclays | DOWNGRADE | Overweight | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 9 | 12 | 1 | 0 | 55% | |
| May 1, 2026 | 7 | 11 | 11 | 1 | 0 | 60% | |
| Apr 1, 2026 | 7 | 11 | 11 | 1 | 0 | 60% | |
| Mar 1, 2026 | 7 | 11 | 11 | 1 | 0 | 60% | |
| Feb 1, 2026 | 8 | 11 | 10 | 1 | 0 | 63% | |
| Jan 1, 2026 | 8 | 13 | 7 | 1 | 0 | 72% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 11, 2026
Clinical Trial
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
Phase Phase 2 — TERMINATED
Jun 10, 2026
Clinical Trial
A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older
Phase Phase 2 — COMPLETED
Jun 9, 2026
clinical_trial_readout
Results Pending: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 (Phase 2) — Completed 18d ago
Trial: A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older
Sponsor: Sanofi P
Jun 5, 2026
Clinical Trial
Safety and Immunogenicity of NVX-CoV2705
Phase Phase 3 — COMPLETED
Jun 4, 2026
Clinical Trial
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older
Phase Phase 2 — COMPLETED
Jun 4, 2026
Clinical Trial
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older
Phase Phase 2 — COMPLETED
Jun 4, 2026
clinical_trial_readout
Results Pending: RIV (recombinant influenza vaccine) (Phase 2) — Completed 62d ago
Trial: Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine an
Jun 4, 2026
clinical_trial_readout
Results Pending: IIV-HD (Phase 2) — Completed 49d ago
Trial: Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine an
May 28, 2026
FDA
Lovenox
WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH)
May 25, 2026
clinical_trial_readout
T-90d Trial Readout: Fitusiran (Phase 3)
Trial: Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B
Sponsor: Genzyme, a Sanofi Company
Phase:
May 23, 2026
clinical_trial_readout
Results Pending: Pandemic flu H5 mRNA vaccine (Phase 2) — Completed 60d ago
Trial: Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older
Sponsor: Sanofi Pasteur
May 20, 2026
FDA
XYZAL ALLERGY 24HR
Supplemental Approval — Labeling — LEVOCETIRIZINE DIHYDROCHLORIDE — TABLET — ORAL
May 18, 2026
clinical_trial_readout
T-90d Trial Readout: Fitusiran (Phase 3)
Trial: Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B
Sponsor: Genzyme, a Sanofi Company
Phase:
May 18, 2026
clinical_trial_readout
T-90d Trial Readout: Amlitelimab (Phase 2)
Trial: A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
Sponsor: Sanofi
Phase: Ph
May 17, 2026
clinical_trial_readout
T-90d Trial Readout: Fitusiran (Phase 3)
Trial: Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B
Sponsor: Genzyme, a Sanofi Company
Phase:
May 11, 2026
clinical_trial_readout
T-90d Trial Readout: Amlitelimab (Phase 2)
Trial: A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
Sponsor: Sanofi
Phase: Ph
May 7, 2026
clinical_trial_readout
T-90d Trial Readout: Amlitelimab (Phase 2)
Trial: A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
Sponsor: Sanofi
Phase: Ph
May 5, 2026
clinical_trial_readout
Results Pending: RIV (recombinant influenza vaccine) (Phase 2) — Completed 32d ago
Trial: Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine an
May 5, 2026
clinical_trial_readout
Results Pending: IIV-HD (Phase 2) — Completed 19d ago
Trial: Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine an
May 1, 2026
clinical_trial_readout
Results Pending: Lunsekimig (Phase 2) — Completed 67d ago
Trial: Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
Sponsor: Sanofi
Phase: Phas
May 1, 2026
clinical_trial_readout
Results Pending: RSV/hMPV vaccine candidate Dose L (Phase 2) — Completed 63d ago
Trial: Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate
Sponsor: Sanofi Pasteur, a Sanofi Company
Phase: Phase 2 | Compl
Apr 30, 2026
short_interest
FTD: SNY — 23,791 shares ($1.1M) failed to deliver
Settlement: 20260430, Price: $46.03, FTD Value: $1,095,099.73, SANOFI-ADR
Apr 20, 2026
FDA
RIFADIN IV
Unavailable: Discontinuation of the manufacture of the drug (Discontinuation of the manufacture of the drug) [Anti-Infective]
Apr 13, 2026
Enforcement
Osinubi v. Sanofi Pasteur Biologics, LLC
Court ruling from District Court, D. Massachusetts. Docket: 1:25-cv-12262
Nov 21, 2016
FDA
SOLIQUA 100/33